Zidesamtinib Patent Expiration

Zidesamtinib was first introduced by Nuvalent Inc in its drug Jideytro on Jul 22, 2026.

Zidesamtinib Patents

Given below is the list of patents protecting Zidesamtinib, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

^NEW

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Jideytro	US12043626	Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds	Sep 30, 2042	Nuvalent
Jideytro	US12630560	Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds	Sep 30, 2042	Nuvalent
Jideytro	US11542278		May 05, 2041	Nuvalent
Jideytro	US12054498	Heteroaromatic Macrocyclic Ether Chemotherapeutic Agents	May 05, 2041	Nuvalent

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List